ライフサイエンスコーパス: occlusive disease

1 isk stratification of patients with arterial occlusive disease.

2 tion for lower extremity peripheral arterial occlusive disease.

3 range, 54-80 years) with peripheral arterial occlusive disease.

4 edema due to diabetic retinopathy or venous occlusive disease.

5 ies of patients suspected of having arterial occlusive disease.

6 s intent on the future management of carotid occlusive disease.

7 Two patients had reversible hepatic veno-occlusive disease.

8 from many causes such as diabetes and venous occlusive disease.

9 infarction in patients with vertebral artery occlusive disease.

10 cardial infarction, stroke, and large-vessel occlusive disease.

11 as therapy for Budd-Chiari syndrome and veno-occlusive disease.

12 ave been identified in patients with retinal occlusive disease.

13 mical assessment of lower extremity arterial occlusive disease.

14 order of testing or the severity of arterial occlusive disease.

15 ess the severity of lower extremity arterial occlusive disease.

16 medical evaluation of patients with retinal occlusive disease.

17 in the sickle mouse precipitates acute vaso-occlusive disease.

18 reatment of atherosclerotic carotid arterial occlusive disease.

19 nal aortic aneurysms and 125 were aortoiliac occlusive disease.

20 100-day mortality was the diagnosis of veno-occlusive disease.

21 istic that predicted the development of veno-occlusive disease.

22 iagnosis of chronic lower-extremity arterial occlusive disease.

23 towards a reduction of its susceptibility to occlusive disease.

24 within the intimal plaque in atherosclerotic occlusive disease.

25 ft patency was 99% for aneurysms and 95% for occlusive disease.

26 erage, 1.33) to prevent progressive vascular occlusive disease.

27 devices for the treatment of femoropopliteal occlusive disease.

28 xicities, with typical mucositis and no veno-occlusive disease.

29 , arterial, and microvascular thrombosis and occlusive disease.

30 imal crossing, location, and stenotic versus occlusive disease.

31 patients with symptomatic atherosclerotic VB occlusive disease.

32 m that protects against ischemia in arterial occlusive disease.

33 17 patients (3%) had hepatic veno-occlusive disease.

34 rucial for the development of pulmonary veno-occlusive disease.

35 , diabetic macular edema, and retinal venous occlusive disease.

36 y less than 3 days to attenuate rebound vaso-occlusive disease.

37 dent Ca(2+) signaling that promotes vascular occlusive disease.

38 saminase and bilirubin without signs of veno-occlusive disease.

39 nction, and a high frequency of hepatic veno-occlusive disease.

40 ped severe hepatotoxicity suggestive of veno-occlusive disease.

41 ge differences in tissue injury in models of occlusive disease.

42 rminants of the severity of tissue injury in occlusive disease.

43 ion in the human kidney affected by vascular occlusive disease.

44 marily the presence and severity of vascular occlusive disease.

45 lenge in clinical treatment of acute thrombo-occlusive diseases.

46 pathogenesis of atherosclerosis and thrombo-occlusive diseases.

47 atic functions that could attenuate vascular occlusive diseases.

48 by participating in the pathogenesis of vaso-occlusive diseases.

49 d macular degeneration, and retinal vascular occlusive diseases.

50 retinopathy of prematurity, and retinal vaso-occlusive diseases.

51 th both asymptomatic and symptomatic carotid occlusive diseases.

52 ent is common in older patients with carotid occlusive diseases.

53 in linking vascular inflammation and thrombo-occlusive diseases.

54 creased proliferation of SMCs contributed to occlusive diseases.

55 apeutic target for the treatment of vascular occlusive diseases.

56 ng toxicities were observed (reversible veno-occlusive disease; 0.180 mg/kg, n=1 and 0.450 mg/kg, n=1

57 ny infection, organ failure, or hepatic veno-occlusive disease (1-year cumulative incidence, 71% vs 8

58 PTCY had significantly higher rates of veno-occlusive disease (14.4% vs TCRalphabeta 4.9%, P = .009)

59 ed and symptomatic aortic aneurysms, 399 for occlusive disease, 18 for infected aortic grafts, and 20

60 obal ischemia (10%), and asymptomatic severe occlusive disease (35%).

61 bdominal aortic aneurysm [AAA]: 47 patients; occlusive disease: 86 patients; both: 12 patients).

62 ,500, respectively), whereas infection, veno-occlusive disease, acute graft-versus-host disease, and

63 24-3.33]; P = .002), and peripheral arterial occlusive disease (adjusted HR, 2.15 [95% CI, 1.26-3.66]

64 Atherosclerotic arterial occlusive disease affecting the lower extremities is als

65 One patient developed nonfatal veno-occlusive disease after induction II.

66 capillary hemangiomatosis and pulmonary veno-occlusive disease, an autosomal recessively inherited di

67 ly explained by large-artery atherosclerotic occlusive disease and abnormal ankle-brachial index (ABI

68 ay contribute to the development of arterial occlusive disease and associated clinical events.

69 passes in high-risk patients with aortoiliac occlusive disease and critical ischemia.

70 renal function is at true risk from vascular occlusive disease and determining who will benefit from

71 Rates of veno-occlusive disease and interstitial pneumonitis were high

72 22 patients (mean age, 69 years) with aortic occlusive disease and MAOD and compared the results with

73 treated with dasatinib, peripheral arterial occlusive disease and other arterial disorders in patien

74 risk of death were patients with aortoiliac occlusive disease and patients undergoing bilateral simu

75 o ultra-rare subtypes of PAH, pulmonary veno-occlusive disease and pulmonary capillary haemangiomatos

76 d well initially, the patient developed veno-occlusive disease and required repeat transplantation at

77 ed deletion of Aplnr manifest pulmonary veno-occlusive disease and right heart failure, detectable at

78 ment of extracranial carotid atherosclerotic occlusive disease and the basis of these recommendations

79 ent of sinusoidal obstruction syndrome (veno-occlusive disease) and by total serum bilirubin levels.

80 ents suspected of having peripheral arterial occlusive disease, and diagnostic performance was simila

81 gic feature of luminal narrowing in vascular occlusive diseases, and nothing is yet known regarding t

82 ; (2) posttransplant fever; (3) hepatic veno-occlusive disease; and (4) use of posttransplant growth

83 e 5A and 6A alleles in AAA (n = 405), aortic occlusive disease (AOD) (n = 123) and controls (n = 405)

84 ntly demonstrated in AAA and atherosclerotic occlusive disease (AOD) tissues (six of six), but in onl

85 proteolytic activity in normal aorta, aorto-occlusive disease (AOD), and AAA by use of a novel in si

86 ruptured and ruptured AAA (rAAA), aortoiliac occlusive disease (AOD), or normal abdominal aorta (NAA)

87 aneurysm (AAA) but more often causes aortic occlusive disease (AOD).

88 Arterial occlusive diseases are major causes of morbidity and mor

89 (presenting as the syndrome of hepatic veno-occlusive disease) are all associated with significant d

90 cause of, respectively, having or not having occlusive disease at the circle of Willis.

91 edure (aortoiliac and infrainguinal arterial occlusive disease) at VQI-participating centers were eli

92 , organ failure, infections, or hepatic veno-occlusive disease between groups.

93 ipid syndrome is a rare cause of ocular vaso-occlusive disease, but is associated with significant sy

94 he contemporary treatment of coronary athero-occlusive disease by percutaneous transluminal coronary

95 months of age as a result of pulmonary veno-occlusive disease, capillary hemorrhage, and pancytopeni

96 istal territory location, and basilar artery occlusive disease carried the poorest prognosis.

97 (NCF) in patients with severe carotid artery occlusive disease, depending on baseline brain perfusion

98 As soon as a veno-occlusive disease diagnosis is established, treatment wi

99 etiology, with patients with pulmonary veno-occlusive disease displaying a lack of microvascular com

100 ypertension and differentiate pulmonary veno-occlusive disease from pulmonary arterial hypertension.

101 Hepatic veno-occlusive disease (HVOD), alias sinusoidal obstruction s

102 s a common mechanism leading to hepatic veno-occlusive disease (HVOD).

103 hy, which mirrors features of human NF1 vaso-occlusive disease, identifies a potential therapeutic ta

104 o worsening pre-existing peripheral arterial occlusive disease in a patient who had received only ima

105 eter-based interventions for lower extremity occlusive disease in an OR/angiography suite.

106 her heterozygosity of Nf1 would lead to vaso-occlusive disease in genetically engineered mice in vivo

107 lso a trend toward an increased risk of veno-occlusive disease in patients with high ferritin.

108 ous limitation in the long-term treatment of occlusive disease in the coronary and peripheral circula

109 is an effective therapy for atherosclerotic occlusive disease in the coronary and peripheral circula

110 stemming from flow reversal,attributable to occlusive disease in the subclavian artery proximal to t

111 dal obstruction syndrome (also known as veno-occlusive disease) in patients during study treatment or

112 ant pathological process in several vascular occlusive diseases, including atherosclerosis and resten

113 tion in native vessels included age, chronic occlusive disease intervention, rotational atherectomy u

114 nial internal carotid artery atherosclerotic occlusive disease is a common ischemic stroke mechanism.

115 Atherosclerotic vertebrobasilar (VB) occlusive disease is a significant etiology of posterior

116 Pulmonary veno-occlusive disease is caused by excessive cell proliferat

117 Severity of tissue injury in occlusive disease is dependent on the extent (number and

118 Chronic lower-extremity occlusive disease is most often manifested by mild sympt

119 ructive syndrome, also known as hepatic veno-occlusive disease, is a potentially life-threatening com

120 dal obstruction syndrome, also known as veno-occlusive disease, is a potentially life-threatening com

121 and D lesions in superficial femoral artery occlusive disease; ISRCTN48164244).

122 result from an intrinsic cerebral arteriolar occlusive disease, little is known about how these proce

123 Variation in clinical practice affects veno-occlusive disease management, mainly in patients who und

124 changes associated with mesenteric arterial occlusive disease (MAOD) are unknown.

125 Veno-occlusive disease may also affect the lungs, and it is t

126 199.5 +/- 14.9 SMCs/HPF) and atherosclerotic occlusive disease (n = 6; 176.4 +/- 13.9 SMCs/HPF), but

127 Veno-occlusive disease occurred twice with cyclophosphamide.

128 No additional cases of veno-occlusive disease occurred.

129 l, 0.14-0.96, P = 0.04), peripheral vascular occlusive disease (odds ratio, 0.25; 95% confidence inte

130 ling was associated with peripheral vascular occlusive disease (odds ratio, 0.4; 95% confidence inter

131 atty liver, atrial thrombus, severe arterial occlusive disease of lower extremities, pleuro-pericardi

132 atation of proximal internal carotid artery, occlusive disease of terminal internal carotid artery, a

133 Symptomatic atherosclerotic occlusive disease of the innominate artery is a threaten

134 nal aortic aneurysm (33 percent) or arterial occlusive disease of the legs (67 percent).

135 Severe veno-occlusive disease of the liver occurred in 9 (21%) of th

136 Additionally, 95 patients developed veno-occlusive disease of the liver.

137 nt acute graft-versus-host disease, and veno-occlusive disease of the liver.

138 Atherosclerotic vascular occlusive disease of the renal arteries does progress, b

139 reversing the loss of kidney function beyond occlusive disease of the renal arteries poses a major cl

140 initiation of pulmonary vasodilators in veno-occlusive disease often leads to increased mortality.

141 ne administration led to severe hepatic veno-occlusive disease on day 6.

142 tion-related mortality; acute toxicity (veno-occlusive disease or acute graft versus-host disease [Gv

143 sease (OR, 2.04; 95% CI, 1.10-3.80), carotid occlusive disease (OR, 2.02; 95% CI, 1.30-3.14), IMPROVE

144 ), GVHD (OR, 2.4; 95% CI, 1.8-3.3), and veno-occlusive disease (OR, 2.2; 95% CI, 1.4-3.6).

145 mpared with normal aorta and atherosclerotic occlusive disease (P < 0.01), and immunoreactive p53 was

146 w L-Ficolin was associated with hepatic veno-occlusive disease (P = .0053, AUC = 0.80).

147 efore the procedure (P<0.01), and peripheral occlusive disease (P=0.04).

148 ug- and toxin-associated PAH, pulmonary veno-occlusive disease, PAH in long-term responders to calciu

149 Peripheral arterial occlusive disease (PAOD) accounts for significant morbid

150 tent claudication due to peripheral arterial occlusive disease (PAOD) is a common cause of pain and d

151 and their heterogeneity in peripheral artery occlusive disease (PAOD) still is limited.

152 Vascular occlusive disease poses a threat to kidney viability, bu

153 Lower extremity peripheral arterial occlusive disease poses a unique challenge to traditiona

154 e hemodynamic impairment associated with the occlusive disease process does not fully account for the

155 ic and heritable PAH and with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis re

156 or heritable PAH and 16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis we

157 with a clinical diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.

158 ne (EIF2AK4) are described in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.

159 Peripheral vascular occlusive disease (PVOD) is a common manifestation of at

160 Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hyp

161 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pulmonar

162 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pulmonar

163 terial hypertension (PAH) and pulmonary veno-occlusive disease (PVOD), respectively.

164 ution of lower extremity peripheral vascular occlusive disease (PVOD).

165 lerotic risk factors and peripheral vascular occlusive disease (PVOD).

166 s, and it is therefore termed pulmonary veno-occlusive disease (PVOD).

167 12) and patients with primary pulmonary veno-occlusive disease (PVOD; n=17).

168 randomized patients with peripheral arterial occlusive disease referred for 64-section multidetector

169 ar abnormalities such as arterial and venous occlusive disease, retinal arteriolar macroaneurysm form

170 related macular degeneration, retinal venous occlusive disease, retinopathy of prematurity, and optic

171 ic retinal disease (DRD), and retinal venous occlusive disease (RVO).

172 of lumen enlargement (growth/remodeling) in occlusive disease, show remarkably wide variation among

173 Classical veno-occlusive disease/sinusoidal obstruction syndrome (VOD/S

174 act the detrimental consequences of vascular occlusive disease, such as stroke or myocardial infarcti

175 therosclerotic disease (LAD) or small-vessel occlusive disease (SVD), 12% developed AF over 1 year wh

176 ccessfully used to treat severe hepatic veno-occlusive disease (sVOD) with multiorgan failure (MOF) i

177 Treosulfan causes less veno-occlusive disease than busulfan and does not require pha

178 novel approach to the treatment of vascular occlusive disease that uses the administration of growth

179 evaluated for the clinical diagnosis of veno-occlusive disease, the occurrence of acute graft-versus-

180 with more severe symptoms of lower-extremity occlusive disease typically have more extensive disease

181 RG and APLNR in patients with pulmonary veno-occlusive disease undergoing lung transplantation were s

182 culation in patients with chronic aortoiliac occlusive disease undergoing subclavian transcatheter ao

183 augmented BOLD MRI response in chronic steno-occlusive disease using a computational framework to pre

184 melphalan group had Bearman grades 1-3 veno-occlusive disease versus 21 (9%) of 239 in the carboplat

185 Rates of veno-occlusive disease (VOD) and thrombotic microangiopathy (

186 ction syndrome (SOS), previously called veno-occlusive disease (VOD) can be a difficult problem after

187 We noted an excess of veno-occlusive disease (VOD) in a clinical trial, and retrosp

188 Hepatic veno-occlusive disease (VOD) is a common complication of high

189 Hepatic veno-occlusive disease (VOD) is one of the most serious compl

190 Hepatic veno-occlusive disease (VOD) is the most common of the regime

191 Veno-occlusive disease (VOD) is the most common regimen-relat

192 Hepatic veno-occlusive disease (VOD) is the most serious regimen-rela

193 Veno-occlusive disease (VOD) is the third leading cause of mo

194 ne patient treated at 9 mg/m2 developed veno-occlusive disease (VOD) of the liver and defined the dos

195 The incidence of hepatic veno-occlusive disease (VOD) was 5% for IV-BU and 1% with TBI

196 Hepatic veno-occlusive disease (VOD), also called sinusoidal obstruct

197 ide for the treatment of severe hepatic veno-occlusive disease (VOD), showing a 23% improvement in da

198 dose limiting toxicity (DLT), including veno-occlusive disease (VOD).

199 2) per day after recognition of hepatic veno-occlusive disease (VOD).

200 The incidence of veno-occlusive disease was 40% (13 of 32 patients) in placebo

201 Arterial occlusive disease was detected by reader 1 in 52, 27, an

202 Arterial occlusive disease was detected by reader 2 in 48, 25, an

203 The day 100 incidence of veno-occlusive disease was lower with Flu/Mel (4%) and Flu/Me

204 e, which are frequently elevated in arterial occlusive disease, we hypothesized that folic acid forti

205 d December 1997, 52 patients with aortoiliac occlusive disease were treated with endovascular grafts.

206 s undergoing carotid intervention for severe occlusive diseases were prospectively recruited.

207 the 12 patients with mild to severe (but not occlusive) disease were misclassified by one category.

208 utive patients with unilateral chronic steno-occlusive disease who underwent acetazolamide-augmented

209 ilure with Flu/Mel and the high rate of veno-occlusive disease with Bu/Cy and Flu/Bu, Flu/Mel/TT may

210 essive primary immunodeficiency disease veno-occlusive disease with immunodeficiency syndrome (VODI),

211 clerosis, chronic lymphocytic leukemia, veno-occlusive disease with immunodeficiency, as well as Myco

212 t lower after treatment of femoral-popliteal occlusive disease with paclitaxel versus nonpaclitaxel d